Skip to main content
. Author manuscript; available in PMC: 2019 Sep 3.
Published in final edited form as: Exp Cell Res. 2008 May 13;314(13):2454–2467. doi: 10.1016/j.yexcr.2008.05.001

Fig. 1 –

Fig. 1 –

Characterization of Armet. A. The endogenous and transfected non-tagged Armet have the same size. Increasing amounts of plasmid encoding non-tagged Armet were transfected into HEK293 cells. Transfected cells were processed for IB for Armet using affinity-purified rabbit anti-Armet. B. Anti-Armet antibody specifically recognizes Armet-6xHis but not Armet-L1–6xHis. pCIneo-Armet-6xHis, pCIneo-Armet-L1–6xHis or pCIneo as control were transfected in HEK293 cells. Twenty-four hours post-transfection cells were processed for IP with anti 6xHis antibody and the precipitates were further analyzed by IB. The input represent 5% of the total proteins used for IP. Arrowhead indicates modified Armet-L1. Laddering bands in lane 4 (upper panel) are non-specific staining. C. Effects of Brefeldin A and tunicamycin on levels and migration of transfected Armet and Armet-L1. HEK293 cells transfected with Armet or Armet-L1 were treated with Tunicamycin (2.5 μg/ml) or Brefeldin A (5 μg/ml.) for 5 h before processed for IB. Arrowhead indicates glycosylated Armet-L1.